| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.052 | 0.8 |
| mRNA | serdemetan | FIMM | pan-cancer | AAC | -0.047 | 0.8 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.053 | 0.8 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | Imatinib | FIMM | pan-cancer | AAC | 0.053 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |